Poston Lab Publications

Episodic recognition memory and the hippocampus in Parkinson's disease: A review.
Das T, Hwang JJ, Poston KL. Cortex. 2018 Dec 4;113:191-209. doi: 10.1016/j.cortex.2018.11.021. [Epub ahead of print] Review.

The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort.
Marek K, Chowdhury S, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Simuni T, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, Toga AW, Mollenhauer B, Galasko D, Chahine LM, Weintraub D, Foroud T, Tosun-Turgut D, Poston K, Arnedo V, Frasier M, Sherer T; Parkinson's Progression Markers Initiative. Ann Clin Transl Neurol. 2018 Oct 31;5(12):1460-1477. doi: 10.1002/acn3.644. eCollection 2018 Dec.

Ultra-Low-Dose ¹⁸F-Florbetaben Amyloid PET Imaging Using Deep Learning with Multi-Contrast MRI Inputs.
Chen KT, Gong E, de Carvalho Macruz FB, Xu J, Boumis A, Khalighi M, Poston KL, Sha SJ, Greicius MD, Mormino E, Pauly JM, Srinivas S, Zaharchuk G. Radiology. 2018 Dec 11:180940. doi: 10.1148/radiol.2018180940. [Epub ahead of print]

Information processing deficit in older adults with HIV infection: A comparison with Parkinson's disease.
Sundaram S, Müller-Oehring EM, Fama R, Brontë-Stewart HM, Poston KL, Goodcase R, Martin T, Prabhakar V, Karpf J, Schulte T. Neuropsychology. 2018 Nov 26. doi: 10.1037/neu0000500. [Epub ahead of print]

Dopamine-related dissociation of cortical and subcortical brain activations in cognitively unimpaired Parkinson’s disease patients OFF and ON medications.
Kim J, Zhang K, Cai W, YorkWilliams S, Ua Cruadhlaoich MAI, Llanes S, Menon V, Poston KL. Neuropsychologia. 2018 Jul 21;119:24-33. doi: 10.1016/j.neuropsychologia.2018.07.024.

Sex differences in progression to mild cognitive impairment and dementia in Parkinson's disease.
Cholerton B, Johnson CO, Fish B, Quinn JF, Chung KA, Peterson-Hiller AL, Rosenthal LS, Dawson TM, Albert MS, Hu SC, Mata IF, Leverenz JB, Poston KL, Montine TJ, Zabetian CP, Edwards KL. Parkinsonism Relat Disord. 2018 May; 50:29-36. doi: 10.1016/j.parkreldis.2018.02.007. Epub 2018 Feb 9.

Longitudinal change of clinical and biological measures in early Parkinson's disease: Parkinson's progression markers initiative cohort.
Simuni T, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, Toga AW, Mollenhauer B, Galasko D, Chahine LM, Weintraub D, Foroud T, Tosun D, Poston K, Arnedo V, Frasier M, Sherer T, Chowdhury S, Marek K; Parkinson's Progression Marker Initiative*. Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27361.

Slower saccadic reading in Parkinson’s disease.
Jehangir N, Yu CY, Song J, Shariati MA, Binder S, Beyer J, Santini V, Poston KL, Liao YJ. PLoS One. 2018 Jan 24;13(1):e0191005. doi: 10.1371/journal.pone.0191005. eCollection 2018.

7T MRI subthalamic nucleus atlas for use with 3T MRI.
Milchenko M, Norris SA, Poston KL, Campbell MC, Ushe M, Perlmutter JS, Snyder AZ. J Med Imaging (Bellingham). 2018 Jan;5(1):015002. doi: 10.1117/1.JMI.5.1.015002. Epub 2018 Jan 8.

Further study of the Montreal Cognitive Assessment’s domain-specific metrics could allow for international data comparison and collaboration.
Hendershott TR, Poston KL. Parkinsonism Relat Disord. 2017 Nov 21. pii: S1353-8020(17)30802-7. doi: 10.1016/j.parkreldis.2017.11.336. [Epub ahead of print] 

Distinct alternations in Parkinson’s medication-state and disease-state connectivity.
Ng B, Varoquaux G, Poline JB, Thirion B, Greicius MD, Poston KL. Neuroimage Clin. 2017 Sep 6;16:575-585. doi: 10.1016/j.nicl.2017.09.004. eCollection 2017.

Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson's disease.
Niethammer M, Tang CC, LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Sarkar A, Siddiqui MS, Tatter SB, Schwalb JM, Poston KL, Henderson JM, Kurlan RM, Richard IH, Sapan CV, Eidelberg D, During MJ, Kaplitt MG, Feigin A. JCI Insight. 2017 Apr 6;2(7):e90133. doi: 10.1172/jci.insight.90133.

Domain-specific accuracy of the Montreal Cognitive Assessment subsections in Parkinson's disease.
Hendershott TR, Zhu D, Llanes S, Poston KL. Parkinsonism Relat Disord. 2017 May;38:31-34. doi: 10.1016/j.parkreldis.2017.02.008. Epub 2017 Feb 7.

Abnormal eye movement behavior during reading in Parkinson's disease.
Yu CY, Lee T, Shariati MA, Santini V, Poston KL, Liao YJ. Parkinsonism Relat Disord. 2016 Nov;32:130-132. doi: 10.1016/j.parkreldis.2016.08.008. Epub 2016 Aug 12.

The effects of dopamine on digit span in Parkinson's disease.
Warden C, Hwang J, Marshall A, Fenesy M, Poston KL. J Clin Mov Disord. 2016 Mar 7;3:5. doi: 10.1186/s40734-016-0033-z. eCollection 2016.

Compensatory neural mechanisms in cognitively unimpaired Parkinson disease.
Poston KL, YorkWilliams S, Zhang K, Cai W, Everling D, Tayim FM, Llanes S, Menon V. Ann Neurol. 2016 Mar;79(3):448-63. doi: 10.1002/ana.24585. Epub 2016 Feb 10.

Do CSF Biomarkers Predict Progression to Cognitive Impairment in Parkinson's disease patients? A Systematic Review. Leaver K, Poston KL. Neuropsychol Rev. 2015 Dec;25(4):411-23. doi: 10.1007/s11065-015-9307-8. Epub 2015 Dec 1.

Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial
Warren Olanow C, Bartus RT, Baumann TL, Factor S, Boulis N, Stacy M, Turner DA, Marks W, Larson P, Starr PA, Jankovic J, Simpson R, Watts R, Guthrie B, Poston K, Henderson JM, Stern M, Baltuch G, Goetz CG, Herzog C, Kordower JH, Alterman R, Lozano AM, Lang AE. Ann Neurol. 2015 Jun 10. doi: 10.1002/ana.24436.

Task-rest modulation of basal ganglia connectivity in mild to moderate Parkinson’s disease
Müller-Oehring EM, Sullivan EV, Pfefferbaum A, Huang NC, Poston KL, Bronte-Stewart HM, Schulte T. Brain Imaging Behav. 2014 Oct 4. [Epub ahead of print]

A disease-specific metabolic brain network associated with corticobasal degeneration
Niethammer M, Tang CC, Feigin A, Allen PJ, Heinen L, Hellwig S, Amtage F, Hanspal E, Vonsattel JP, Poston KL, Meyer PT, Leenders KL, Eidelberg D. Brain. 2014 Nov;137(Pt 11):3036-46. doi: 10.1093/brain/awu256. Epub 2014 Sep 9.

Network correlates of disease severity in multiple system atrophy.
Poston KL, Tang CC, Eckert T, Dhawan V, Frucht S, Vonsattel JP, Fahn S, Eidelberg D. Neurology. 2012; 78 (16): 1237-44

AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Thomas K, Sarkar A, Siddiqui MS, Tatter SB, Schwalb JM, Poston KL, Henderson JM, Kurlan RM, Richard IH, Van Meter L, Sapan CV, During MJ, Kaplitt MG, Feigin A. Lancet Neurol. 2011; 10 (4): 309-19

Functional brain networks and abnormal connectivity in the movement disorders.
Poston KL, Eidelberg D. Neuroimage. 2011

Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease.
Tang CC, Poston KL, Dhawan V, Eidelberg D. J Neurosci. 2010; 30 (3): 1049-56

Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis.
Tang CC, Poston KL, Eckert T, Feigin A, Frucht S, Gudesblatt M, Dhawan V, Lesser M, Vonsattel JP, Fahn S, Eidelberg D. Lancet Neurol. 2010; 9 (2): 149-58

FDG PET in the Evaluation of Parkinson's Disease.
Poston KL, Eidelberg D. PET Clin. 2010; 5 (1): 55-64

Fragile X-associated tremor/ataxia syndrome (FXTAS) with myoclonus.
Poston KL, McGovern RA, Goldman JS, Caccappolo E, Mazzoni P. Mov Disord. 2010; 25 (4): 514-6

Action tremor of the legs in essential tremor: prevalence, clinical correlates, and comparison with age-matched controls.
Poston KL, Rios E, Louis ED. Parkinsonism Relat Disord. 2009; 15 (8): 602-5

Network biomarkers for the diagnosis and treatment of movement disorders.Poston KL, Eidelberg D. Neurobiol Dis. 2009; 35 (2): 141-7

Movement disorder emergencies.
Poston KL, Frucht SJ. J Neurol. 2008: 255 Suppl 4 2-13

Zydis selegiline in the management of Parkinson's disease.
Poston KL, Waters C. Expert Opin Pharmacother. 2007; 8 (15): 2615-24